Advertisement

Topics

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

05:42 EDT 17 May 2018 | News-Medical.net

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

Original Article: Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

NEXT ARTICLE

More From BioPortfolio on "Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...